Elisabet I Nielsen

List of Publications by Year
in descending order

39 papers	1,557 citations	430442 18 h-index	315357 38 g-index
39 all docs	39 docs citations	39 times ranked	1570 citing authors

#	Article	IF	Citations
1	Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs. Pharmacological Reviews, 2013, 65, 1053-1090.	7.1	248
2	Pharmacokinetic/Pharmacodynamic (PK/PD) Indices of Antibiotics Predicted by a Semimechanistic PKPD Model: a Step toward Model-Based Dose Optimization. Antimicrobial Agents and Chemotherapy, 2011, 55, 4619-4630.	1.4	198
3	Semimechanistic Pharmacokinetic/Pharmacodynamic Model for Assessment of Activity of Antibacterial Agents from Time-Kill Curve Experiments. Antimicrobial Agents and Chemotherapy, 2007, 51, 128-136.	1.4	143
4	From Therapeutic Drug Monitoring to Modelâ€informed Precision Dosing for Antibiotics. Clinical Pharmacology and Therapeutics, 2021, 109, 928-941.	2.3	131
5	Developmental Pharmacokinetics of Gentamicin in Preterm and Term Neonates. Clinical Pharmacokinetics, 2009, 48, 253-263.	1.6	71
6	Pharmacokinetic-Pharmacodynamic Model for Gentamicin and Its Adaptive Resistance with Predictions of Dosing Schedules in Newborn Infants. Antimicrobial Agents and Chemotherapy, 2012, 56, 179-188.	1.4	71
7	A Neonatal Amikacin Covariate Model Can Be Used to Predict Ontogeny of Other Drugs Eliminated Through Glomerular Filtration in Neonates. Pharmaceutical Research, 2014, 31, 754-767.	1.7	67
8	Development and Evaluation of a Gentamicin Pharmacokinetic Model That Facilitates Opportunistic Gentamicin Therapeutic Drug Monitoring in Neonates and Infants. Antimicrobial Agents and Chemotherapy, 2016, 60, 4869-4877.	1.4	51
9	Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs. Pharmaceutical Research, 2016, 33, 1115-1125.	1.7	46
10	Handling interoccasion variability in modelâ€based dose individualization using therapeutic drug monitoring data. British Journal of Clinical Pharmacology, 2019, 85, 1326-1336.	1.1	45
11	Predicting In Vitro Antibacterial Efficacy across Experimental Designs with a Semimechanistic Pharmacokinetic-Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2011, 55, 1571-1579.	1.4	40
12	Imitation of Î²-lactam binding enables broad-spectrum metallo-Î²-lactamase inhibitors. Nature Chemistry, 2022, 14, 15-24.	6.6	39
13	A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants. Journal of Antimicrobial Chemotherapy, 2015, 70, 3051-3060.	1.3	35
14	Dynamic interaction of colistin and meropenem on a WT and a resistant strain ofPseudomonas aeruginosaas quantified in a PK/PD model. Journal of Antimicrobial Chemotherapy, 2016, 71, 1279-1290.	1.3	35
15	A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 69-79.	0.8	33
16	A pharmacokineticâ€“pharmacodynamic (PKPD) model based onin vitrotimeâ€“kill data predicts thein vivoPK/PD index of colistin. Journal of Antimicrobial Chemotherapy, 2016, 71, 1881-1884.	1.3	26
17	Can a pharmacokinetic/pharmacodynamic (PKPD) model be predictive across bacterial densities and strains? External evaluation of a PKPD model describing longitudinal in vitro data. Journal of Antimicrobial Chemotherapy, 2017, 72, 3108-3116.	1.3	23
18	Effects of Hospital-Based Comprehensive Medication Reviews Including Postdischarge Follow-up on Older Patientsâ€™ Use of Health Care. JAMA Network Open, 2021, 4, e216303.	2.8	22

#	Article	IF	Citations
19	Population Pharmacokinetic Analysis of Vaginally and Intravenously Administered Oxytocin in Postmenopausal Women. Journal of Clinical Pharmacology, 2017, 57, 1573-1581.	1.0	20
20	Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring. Cancer Chemotherapy and Pharmacology, 2017, 80, 343-353.	1.1	20
21	Pharmacodynamics of immune response biomarkers of interest for evaluation of treatment effects in bacterial infections. International Journal of Antimicrobial Agents, 2020, 56, 106059.	1.1	18
22	Research priorities towards precision antibiotic therapy to improve patient care. Lancet Microbe, The, 2022, 3, e795-e802.	3.4	17
23	Medication Reviews Bridging Healthcare (MedBridge): Study protocol for a pragmatic cluster-randomised crossover trial. Contemporary Clinical Trials, 2017, 61, 126-132.	0.8	15
24	A non-linear mixed effect model for innate immune response: In vivo kinetics of endotoxin and its induction of the cytokines tumor necrosis factor alpha and interleukin-6. PLoS ONE, 2019, 14, e0211981.	1.1	15
25	A novel mechanism-based pharmacokineticâ€“pharmacodynamic (PKPD) model describing ceftazidime/avibactam efficacy against Î²-lactamase-producing Gram-negative bacteria. Journal of Antimicrobial Chemotherapy, 2020, 75, 400-408.	1.3	14
26	Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinsonâ€™s disease patients. European Journal of Clinical Pharmacology, 2018, 74, 1299-1307.	0.8	13
27	Extension of Pharmacokinetic/Pharmacodynamic Time-Kill Studies To Include Lipopolysaccharide/Endotoxin Release from Escherichia coli Exposed to Cefuroxime. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	13
28	Combination of polymyxin B and minocycline against multidrug-resistant Klebsiella pneumoniae: interaction quantified by pharmacokinetic/pharmacodynamic modelling from in vitro data. International Journal of Antimicrobial Agents, 2020, 55, 105941.	1.1	13
29	A pharmacokineticâ€“pharmacodynamic model characterizing the emergence of resistantEscherichia colisubpopulations during ertapenem exposure. Journal of Antimicrobial Chemotherapy, 2016, 71, 2521-2533.	1.3	12
30	The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukinâ€6 and Câ€reactive protein by modelling. British Journal of Clinical Pharmacology, 2018, 84, 490-500.	1.1	12
31	A Cross-Sectional Study Assessing Appropriateness Of Inhaled Corticosteroid Treatment In Primary And Secondary Care Patients With COPD In Sweden . International Journal of COPD, 2019, Volume 14, 2451-2460.	0.9	12
32	Evaluation of automated time-lapse microscopy for assessment of in vitro activity of antibiotics. Journal of Microbiological Methods, 2017, 132, 69-75.	0.7	11
33	Critical inhaler technique errors in Swedish patients with COPD: a cross-sectional study analysing video-recorded demonstrations. Npj Primary Care Respiratory Medicine, 2021, 31, 5.	1.1	7
34	Intervention fidelity and process outcomes of medication reviews including postâ€discharge followâ€up in older hospitalized patients: Process evaluation of the MedBridge trial. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 1021-1029.	0.7	6
35	Population pharmacokinetics of cefotaxime in intensive care patients. European Journal of Clinical Pharmacology, 2022, 78, 251-258.	0.8	5
36	Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli. International Journal of Antimicrobial Agents, 2018, 51, 399-406.	1.1	4

#	Article	IF	Citations
37	Changes in critical inhaler technique errors in inhaled COPD treatment â€“ A one-year follow-up study in Sweden. Respiratory Medicine, 2022, 197, 106849.	1.3	3
38	Continuous infusion of piperacillinâ€tazobactam significantly improves target attainment in children with cancer and fever. Cancer Reports, 2022, 5, e1585.	0.6	2
39	Quantitation of seven sedative and analgesic drugs in whole blood from intensive care patients using liquid chromatography mass spectrometry. Toxicologie Analytique Et Clinique, 2021, 33, 327-327.	0.1	1